At NUVISAN, we are dedicated to providing you with exceptional DMPK services that support you in making informed decisions throughout the drug discovery and development process. During the drug discovery phase, the goal is to guide a focused and fast optimization of lead structures toward a viable clinical candidate. A suitable screening tree is a critical step for identifying and potentially overcoming ADME liabilities as early as possible. Initially, state-of-the-art in vitro ADME assays are performed, including the characterization of metabolic stability (liver microsomes and hepatocytes), permeability, plasma protein binding, characterization of the CYP profile (CYP inhibition, CYP induction. CYP phenotyping), and metabolite identification. Some of our assays can be performed as high-throughput or radiolabeled assays and can be adapted to your needs. These thorough in vitro investigations facilitate and complement the identification of suitable compounds for in vivo pharmacokinetic studies. Depending on your compound profile and needs, in vivo study designs are optimized with our DMPK experts. Each of our different study designs (e.g., with regard to a variety of available administration routes, different sampling technologies, or mono/cassette dosing) is performed using state-of-the-art methodologies. High animal welfare standards that align with the 3R-concept and AAALAC accreditation are the basis of our work. Furthermore, tailor-made studies for specific ADME questions can be provided, such as tissue distribution or elimination studies (including renal and hepatic drug clearance). Finally, the test of different formulations to identify the best one for other in vivo studies is our expertise. All studies are supported by our experienced bioanalysts.